Bfsg LLC Acquires New Stake in Sanofi (NASDAQ:SNY)

Bfsg LLC acquired a new stake in shares of Sanofi (NASDAQ:SNY) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,425 shares of the company’s stock, valued at approximately $71,000.

Several other large investors also recently added to or reduced their stakes in SNY. IFP Advisors Inc lifted its stake in Sanofi by 68.3% during the third quarter. IFP Advisors Inc now owns 2,820 shares of the company’s stock worth $151,000 after purchasing an additional 1,144 shares during the last quarter. Koshinski Asset Management Inc. bought a new stake in Sanofi during the third quarter worth about $203,000. Coastline Trust Co bought a new stake in Sanofi during the third quarter worth about $631,000. UMB Bank n.a. lifted its stake in Sanofi by 38.8% during the third quarter. UMB Bank n.a. now owns 1,876 shares of the company’s stock worth $101,000 after purchasing an additional 524 shares during the last quarter. Finally, Simplicity Solutions LLC lifted its stake in Sanofi by 2.5% during the third quarter. Simplicity Solutions LLC now owns 75,440 shares of the company’s stock worth $4,047,000 after purchasing an additional 1,848 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Down 1.6 %

Shares of NASDAQ:SNY opened at $48.56 on Friday. Sanofi has a 1 year low of $42.63 and a 1 year high of $56.26. The company has a market cap of $122.84 billion, a PE ratio of 20.92, a P/E/G ratio of 1.41 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The stock’s 50-day moving average is $47.65 and its 200 day moving average is $48.45.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a net margin of 12.56% and a return on equity of 27.47%. The business had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion. Sell-side analysts anticipate that Sanofi will post 4.09 EPS for the current year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be given a dividend of $1.478 per share. This represents a yield of 2.98%. This is a boost from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s payout ratio is presently 58.47%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Finally, Morgan Stanley assumed coverage on Sanofi in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Sanofi has a consensus rating of “Hold” and a consensus price target of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.